This grant application requests five years of renewed support for the Arizona Alzheimer's Disease Core Center (ADCC). The ADCC is intended to optimize the development and use of its Cores, advance the scientific understanding, unusually early detection, and tracking of AD, and the accelerated evaluation of AD modifying and prevention therapies, promote additional organizational investments, and provide a model of statewide collaboration in AD research. The Administrative Core provides the leadership and support needed to optimize the development, interactions, and use of its Cores. It works closely with researchers inside and outside Arizona, the National Alzheimer's Coordinating Center (NACC), and other AD Centers to promote the development and progress of AD-related studies and collaborations. It administers a program for the statewide solicitation, competitive review, and support of pilot studies. It helps solve the challenges and fulfill the opportunities associated with the ADCC's statewide collaborative model and ensures the ADCC's accountability to the NIA. The Clinical Core maintains a large pool of clinically well characterized and annually assessed research subjects for the scientific study of AD and aging, including patients with AD, other dementias, and mild cognitive impairment (MCI);normal controls, most of whom are enrolled in a brain donation program, and a growing number of Latino and Native American research subjects. This Core ensures the comparability and the productive and appropriate use of subjects, DNA, blood samples, and data from its six clinical sites. It also promotes the productive and appropriate scientific use of subjects from its independently supported APOE, Brain and Body Donation, and Clinical Therapeutics Registry Programs. The Data Management and Statistics Core maintains the ADCC's database, helps ensure the quality of data and the protection of subject confidentiality, and provides statistical services and image-analysis resources in a manner that best serves the needs of the statewide ADCC. It works closely with researchers, NACC, and other AD Centers, sharing data in the most productive, timely, and appropriate way. The Neuropathology Core provides neuropathological diagnoses and extremely high-quality brain and body tissues from expired Clinical Core and ancillary program subjects to support research studies in Arizona and around the world, helping to address a critical need in the AD research community. The Education and Information Core provides training, innovative educational and outreach programs, and strategic partnerships to promote the development of AD-related researchers, address needs of professional and family caregivers, provide information about the ADCC, address unmet needs of Arizona's Native American and rapidly growing Latino communities, and assist in the Clinical Core enrollment and study of these understudied groups.

Public Health Relevance

The Arizona Alzheimer's Disease Center (ADC) is the National Institute on Aging's (NIA's) first statewide AD Center, the only one in Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on shared scientific resources and complementary strengths from different disciplines and institutions to advance the scientific understanding, unusually early detection and tracking of AD, help address the unmet needs of Native American and Latino communities, and find demonstrably effective treatments to prevent AD symptoms as soon as possible.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-13
Application #
8501197
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
2001-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$1,356,753
Indirect Cost
$242,687
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Sabbagh, Marwan N; Shi, Jiong; Lee, Moonhee et al. (2018) Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings. BMC Neurol 18:155
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Walker, Douglas G; Tang, Tiffany M; Lue, Lih-Fen (2018) Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains. Exp Neurol 309:91-106
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Wu, Jianfeng; Zhang, Jie; Shi, Jie et al. (2018) HIPPOCAMPUS MORPHOMETRY STUDY ON PATHOLOGY-CONFIRMED ALZHEIMER'S DISEASE PATIENTS WITH SURFACE MULTIVARIATE MORPHOMETRY STATISTICS. Proc IEEE Int Symp Biomed Imaging 2018:1555-1559
Cabrera, Erwin; Mathews, Paul; Mezhericher, Emiliya et al. (2018) A? truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis 1864:208-225
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Tariot, Pierre N; Lopera, Francisco; Langbaum, Jessica B et al. (2018) The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's diseas Alzheimers Dement (N Y) 4:150-160
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Beach, Thomas G; Serrano, Geidy E; Kremer, Thomas et al. (2018) Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol 77:793-802

Showing the most recent 10 out of 794 publications